Whitney Ijem
Stock Analyst at Canaccord Genuity
(3.33)
# 1,014
Out of 4,918 analysts
97
Total ratings
45.45%
Success rate
4.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $11 → $10 | $2.99 | +234.45% | 9 | Jul 25, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $92 → $105 | $86.70 | +21.11% | 8 | Jul 18, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $9 → $11 | $2.72 | +305.16% | 10 | Jun 3, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $74 → $54 | $11.35 | +375.77% | 6 | Jun 3, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $53 → $52 | $36.32 | +43.17% | 3 | May 16, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | $68 → $66 | $11.93 | +453.23% | 6 | May 13, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $385 → $390 | $394.22 | -1.07% | 8 | Mar 21, 2025 | |
| GBIO Generation Bio Co. | Maintains: Buy | $90 | $4.16 | +2,063.46% | 2 | Mar 17, 2025 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $18 → $6 | $0.66 | +806.21% | 6 | Mar 13, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $121 → $136 | $27.26 | +398.90% | 8 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $408 → $424 | $456.47 | -7.11% | 8 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 | $5.75 | +4,421.74% | 6 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $150 | $15.90 | +843.40% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $93 → $84 | $56.90 | +47.63% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $112.48 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $120 → $240 | $3.93 | +6,006.87% | 4 | Jul 23, 2019 |
Rocket Pharmaceuticals
Jul 25, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $2.99
Upside: +234.45%
Rhythm Pharmaceuticals
Jul 18, 2025
Maintains: Buy
Price Target: $92 → $105
Current: $86.70
Upside: +21.11%
Taysha Gene Therapies
Jun 3, 2025
Maintains: Buy
Price Target: $9 → $11
Current: $2.72
Upside: +305.16%
Intellia Therapeutics
Jun 3, 2025
Maintains: Buy
Price Target: $74 → $54
Current: $11.35
Upside: +375.77%
Palvella Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $53 → $52
Current: $36.32
Upside: +43.17%
Arcturus Therapeutics Holdings
May 13, 2025
Maintains: Buy
Price Target: $68 → $66
Current: $11.93
Upside: +453.23%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $385 → $390
Current: $394.22
Upside: -1.07%
Generation Bio Co.
Mar 17, 2025
Maintains: Buy
Price Target: $90
Current: $4.16
Upside: +2,063.46%
Tenaya Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $18 → $6
Current: $0.66
Upside: +806.21%
Ultragenyx Pharmaceutical
Feb 18, 2025
Maintains: Buy
Price Target: $121 → $136
Current: $27.26
Upside: +398.90%
Feb 12, 2025
Upgrades: Hold
Price Target: $408 → $424
Current: $456.47
Upside: -7.11%
Nov 14, 2024
Maintains: Buy
Price Target: $260
Current: $5.75
Upside: +4,421.74%
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $15.90
Upside: +843.40%
Oct 30, 2024
Maintains: Hold
Price Target: $93 → $84
Current: $56.90
Upside: +47.63%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $112.48
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $120 → $240
Current: $3.93
Upside: +6,006.87%